The Work We Fund

Funded projects
1,250+
Men's Health Partners
20
Countries
20
We work closely with our global men's health partners to ensure collaboration, transparency and accountability for every project we fund. We monitor this through report cards which detail what we seek to achieve, key measures and the impact.
Prostate Cancer
"Together with the brightest minds in research, we aim to achieve significant breakthroughs in the hope of beating prostate cancer. Our disruptive funding approach identifies revolutionary ways to accelerate health outcomes by creating strong, global collaborative teams." Dr. Colleen Nelson, Global Scientific Chair.
Men's Health
"One Mo can help change the face of men’s health through the powerful conversations created globally during Movember. Men have the chance to confidently discuss men’s health with people around them, resulting in men taking action early, helping change and save lives." Paul Villanti, Executive Director, Programs
Mental health and suicide prevention
“The number of men taking their own lives around the world is one of the biggest challenges of our time. Movember is working to ensure all men and boys look after their mental health and are comfortable to seek help when they’re struggling.”
Brendan Maher, Global Director, Mental Health and Suicide Prevention.
Testicular Cancer
“Despite being the 2nd most common cancer in young men, testicular cancer is often a forgotten cancer due to early detection and treatment. Our projects look at underinvested areas such as improving access to healthcare services and treatment options for relapse” Paul Villanti, Executive Director, Programs.

The Movember Revolutionary Team Award: Adaptive Response to Targeting the Androgen Axis: A Strategic Offensive on Resistance

Movember Funding to Date

AUD 6,250,000

What we seek to achieve

These discoveries will revolutionise the treatment of advanced prostate cancer by investigating the adaptive response of prostate cancer cells and tumours to androgen targeted therapies (ATTs) and strategically developing drugs to be used in combination or in sequence with ATT in order to improve and prolong the lives of men living with advanced prostate cancer.

Country
Australia
Implemented by
Movember Foundation and Prostate Cancer Foundation of Australia
Project start date
July 2014
Project Status
Project Complete

About the project

This team’s expertise in prostate cancer and highly relevant combination of skill sets and biological resources will enable them to uncover innovative insights of the adaptive response of prostate cancer to ATT. They have chosen specific biological pathways to be investigated because they have convincing evidence that they are consistently activated in men with prostate cancer and their corresponding tumour models in response to ATT, they have significant implications in cancer progression and treatment resistance and they have novel and re-purposed drugs to target these pathways.

The ultimate goal of this program is to capitalise on adaptive pathways activated by inhibition of the androgen axis to identify and strategically develop drugs to be used in combination or in sequence with ATT to improve outcomes in advanced prostate cancer.

The MRTA has provided an excellent team-based, collaborative and translational environment to provide a range of training and professional development opportunities. The MRTA1 team is highly integrated and interacts well with the other two MRTA teams nationally and internationally (Canada).

The MRTA1 management committee has also established a scientific advisory board (SAB) comprising senior experts with expertise in both clinical and basic prostate cancer research.

>
Page 1 of 29